Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells

Thomas Efferth1, Marco Giaisi, Annette Merling

  • 1Pharmaceutical Biology of Natural Products, German Cancer Research Center, Heidelberg, Germany.

Plos One
|August 2, 2007
PubMed
Abstract

Insights

Artesunate (ART) induces apoptosis in drug-resistant leukemia cells via mitochondrial reactive oxygen species (ROS) generation, overcoming chemotherapy resistance. ART also synergizes with Doxorubicin, offering new combination therapy potential.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Chemotherapy resistance is a major challenge in cancer treatment, necessitating novel therapeutic agents.
  • Artesunate (ART), an anti-malarial drug, shows promise against various cancer cell lines and lacks severe side effects.
  • The precise molecular mechanisms of ART's anti-cancer activity remain largely unelucidated.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying Artesunate (ART)-induced apoptosis in T-cell leukemias.
  • To determine if ART can overcome Doxorubicin resistance in leukemia cells.
  • To explore the potential synergistic effects of ART in combination with Doxorubicin.

Main Methods:

  • Utilized a Doxorubicin-resistant T-cell leukemia model system.
  • Investigated ART's cytotoxic effects and the role of mitochondrial pathways and reactive oxygen species (ROS).
  • Assessed the impact of the antioxidant N-Acetyl-Cysteine (NAC) on ART-induced apoptosis.

Main Results:

  • ART induces apoptosis in leukemic T cells primarily through the mitochondrial pathway, involving ROS generation.
  • ART effectively overcomes Doxorubicin resistance, inducing apoptosis in resistant leukemia cells.
  • ART demonstrates a synergistic effect with Doxorubicin, enhancing cancer cell death through distinct mechanisms.

Conclusions:

  • Artesunate (ART) offers a novel mechanism for inducing apoptosis, distinct from traditional chemotherapy agents like Doxorubicin.
  • ART has the potential to overcome drug resistance in leukemia and other cancers.
  • ART may be a valuable component in combination cancer therapies, targeting resistant tumors.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...